CTSO — Cytosorbents Income Statement
0.000.00%
Last trade - 00:00- $58.85m
- $69.57m
- $35.59m
- 51
- 28
- 32
- 30
Annual income statement for Cytosorbents, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 41 | 43.2 | 34.7 | 31.1 | 35.6 |
| Cost of Revenue | |||||
| Gross Profit | 30 | 32.1 | 20.7 | 22 | 25.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 51.4 | 65.9 | 66.2 | 63 | 52.4 |
| Operating Profit | -10.4 | -22.7 | -31.5 | -31.9 | -16.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.96 | -25.3 | -33.9 | -30.1 | -22.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.84 | -24.6 | -32.8 | -29.2 | -20.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.84 | -24.6 | -32.8 | -29.2 | -20.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.84 | -24.6 | -32.8 | -29.2 | -20.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.202 | -0.566 | -0.744 | -0.645 | -0.377 |